…
Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions in Canada and the United States. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; provision of apparel and merchandising solutions; manufactures and sells hemp infused beverages; and supplies pharmaceutical products. The company is headquartered in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Isodiol International Inc develops, manufactures and distributes hemp-derived cannabinoid ingredients and consumer products for wellness and nutraceutical markets. Long-term growth may be supported by expanding global demand for regulated cannabinoid products, product innovation and the company's integrated manufacturing capabilities. Investors may find exposure to the evolving CBD/hemp sector and an upstream production footprint attractive.
Material risks include regulatory and legal uncertainty around cannabinoid products, limited liquidity and public reporting as an OTC Pink-listed small company, dependence on successful execution and external financing to scale, and strong competition.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 |
| Income before tax | -120.91M | -35.73M | -4.29M | -6.71M | -0.72M |
| Minority interest | 0.00M | 0.00M | 0.00M | - | - |
| Net income | -125.91M | -36.02M | -4.29M | -6.71M | -0.72M |
| Selling general administrative | 36.92M | 30.06M | 3.44M | 1.92M | 0.72M |
| Gross profit | 7.38M | 8.88M | 0.13M | 0.01M | 0.00M |
| Reconciled depreciation | 2.06M | 1.11M | - | - | - |
| Ebit | -38.48M | -22.98M | -3.06M | -6.65M | -0.72M |
| Ebitda | -112.88M | -34.62M | - | - | - |
| Non operating income net other | 0.00M | 0.00M | 0.00M | - | - |
| Operating income | -31.72M | -22.89M | -3.45M | -1.91M | -0.72M |
| Other operating expenses | 0.00M | 0.00M | 0.00M | - | - |
| Interest expense | 5.97M | 0.00M | 0.00M | 0.00M | 0.00M |
| Tax provision | -0.30M | 0.29M | - | - | - |
| Net interest income | -5.97M | -0.00M | -0.07M | - | - |
| Extraordinary items | 0.00M | 0.00M | 0.00M | - | - |
| Non recurring | 0.00M | 0.00M | 0.00M | - | - |
| Other items | 0.00M | 0.00M | 0.00M | - | - |
| Income tax expense | -0.30M | 0.29M | 0.00M | 0.00M | 0.00M |
| Total revenue | 22.25M | 19.14M | 0.36M | 0.01M | 0.00M |
| Total operating expenses | 53.96M | 42.03M | 3.81M | 0.00M | 0.00M |
| Cost of revenue | 14.87M | 10.25M | 0.23M | 0.00M | 0.00M |
| Total other income expense net | -83.23M | -12.84M | -0.76M | -4.74M | -4.74M |
| Discontinued operations | -5.30M | -5.30M | -5.30M | - | - |
| Net income from continuing ops | -120.61M | -36.02M | -4.29M | -6.71M | -0.72M |
| Net income applicable to common shares | -125.91M | -36.02M | -4.29M | -6.71M | -0.72M |
| Preferred stock and other adjustments | 0.00M | 0.00M | 0.00M | - | - |
| Breakdown | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 |
| Total assets | 23.62M | 54.47M | 2.28M | 0.37M | 0.06M |
| Intangible assets | 0.00M | 8.15M | 0.00M | - | - |
| Other current assets | 0.00M | 0.00M | 0.00M | 0.03M | 0.05M |
| Total liab | 16.69M | 6.70M | 0.37M | 0.95M | 0.33M |
| Total stockholder equity | 6.93M | 47.77M | 1.90M | -0.57M | -0.27M |
| Deferred long term liab | 0.00M | 0.29M | 0.11M | - | - |
| Other current liab | 3.05M | 5.13M | 0.00M | - | - |
| Common stock | 176.98M | 90.14M | 14.34M | 6.11M | 0.45M |
| Capital stock | 176.98M | - | - | - | - |
| Retained earnings | -175.81M | -49.90M | -13.88M | -7.41M | -0.72M |
| Other liab | 0.00M | 0.00M | 0.00M | - | - |
| Good will | 0.00M | 13.03M | 0.00M | - | - |
| Other assets | 2.16M | 8.81M | 0.11M | - | - |
| Cash | 0.40M | 15.55M | 0.72M | 0.08M | 0.01M |
| Total current liabilities | 11.50M | 6.70M | 0.38M | 0.95M | 0.33M |
| Net debt | 7.69M | - | - | - | - |
| Short term debt | 0.00M | 0.00M | 0.00M | 0.72M | 0.25M |
| Short long term debt | 2.91M | 0.00M | 0.25M | 0.72M | 0.25M |
| Other stockholder equity | 5.76M | 7.52M | 1.44M | 0.73M | 0.01M |
| Property plant equipment | 1.62M | 1.06M | 0.06M | - | - |
| Total current assets | 19.84M | 22.84M | 1.36M | 0.37M | 0.06M |
| Long term investments | 0.00M | 0.87M | 0.86M | - | - |
| Net tangible assets | 6.93M | 26.88M | 1.90M | -0.57M | -0.27M |
| Short term investments | 2.47M | 0.00M | 0.62M | - | - |
| Net receivables | 13.90M | 4.97M | 0.15M | 0.05M | 0.00M |
| Long term debt | 5.19M | 0.00M | 0.00M | - | - |
| Inventory | 0.86M | 1.84M | 0.43M | 0.21M | - |
| Accounts payable | 5.48M | 1.57M | 0.13M | 0.23M | 0.08M |
| Total permanent equity | 0.00M | 0.00M | 0.00M | - | - |
| Noncontrolling interest in consolidated entity | 0.00M | 0.00M | 0.00M | - | - |
| Temporary equity redeemable noncontrolling interests | 0.00M | 0.00M | 0.00M | - | - |
| Accumulated other comprehensive income | 0.00M | 0.00M | 0.00M | - | - |
| Additional paid in capital | 0.00M | 0.00M | 0.00M | - | - |
| Common stock total equity | 0.00M | 0.00M | 0.00M | - | - |
| Preferred stock total equity | 0.00M | 0.00M | 0.00M | - | - |
| Retained earnings total equity | 0.00M | 0.00M | 0.00M | - | - |
| Treasury stock | 0.00M | 0.00M | 0.00M | - | - |
| Accumulated amortization | 0.00M | 0.00M | 0.00M | - | - |
| Non currrent assets other | 3.78M | -0.00M | -0.00M | - | - |
| Deferred long term asset charges | 0.00M | 0.00M | 0.00M | - | - |
| Non current assets total | 3.78M | 31.63M | 0.92M | - | - |
| Capital lease obligations | 0.00M | 0.00M | 0.00M | - | - |
| Long term debt total | 0.00M | 0.00M | 0.00M | - | - |
| Breakdown | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 |
| Investments | -2.54M | -2.54M | -2.54M | -0.25M | -0.25M |
| Change to liabilities | 7.66M | 0.20M | 0.10M | 0.26M | 0.08M |
| Total cashflows from investing activities | -16.48M | -16.64M | -0.39M | -0.29M | -0.29M |
| Net borrowings | 7.90M | 7.90M | -0.35M | 0.77M | 0.25M |
| Total cash from financing activities | 24.70M | 55.09M | 3.84M | 1.25M | 0.51M |
| Change to operating activities | -1.78M | -0.70M | -0.07M | 0.03M | -0.05M |
| Net income | -125.91M | -36.02M | -4.29M | -6.71M | -0.72M |
| Change in cash | -15.15M | 14.83M | 0.61M | 0.07M | 0.01M |
| Begin period cash flow | 15.55M | 0.72M | 0.11M | - | - |
| End period cash flow | 0.40M | 15.55M | 0.72M | 0.11M | - |
| Total cash from operating activities | -24.03M | -23.48M | -2.84M | -1.18M | -0.50M |
| Issuance of capital stock | 15.80M | - | - | - | - |
| Depreciation | 1.95M | 0.98M | 0.98M | - | - |
| Other cashflows from investing activities | 1.33M | 0.16M | 0.16M | - | - |
| Dividends paid | 0.00M | 0.00M | 0.00M | - | - |
| Change to inventory | 0.98M | -1.83M | -0.15M | -0.21M | -0.21M |
| Change to account receivables | -7.99M | -2.98M | -0.08M | -0.03M | -0.00M |
| Sale purchase of stock | 0.00M | 0.00M | 3.66M | 0.28M | 0.26M |
| Other cashflows from financing activities | -0.88M | -1.57M | -0.05M | 0.20M | 0.20M |
| Change to netincome | 100.94M | 16.75M | 1.65M | 5.48M | 0.20M |
| Capital expenditures | 0.93M | 1.21M | 0.39M | 0.04M | 0.04M |
| Change receivables | 0.00M | 0.00M | 0.00M | - | - |
| Cash flows other operating | 0.00M | 0.00M | 0.00M | - | - |
| Exchange rate changes | 0.00M | 0.00M | 0.00M | - | - |
| Cash and cash equivalents changes | 0.00M | 0.00M | 0.00M | - | - |
| Change in working capital | -1.43M | -5.01M | - | - | - |
| Stock based compensation | 0.48M | - | - | - | - |
| Other non cash items | 18.99M | 9.28M | - | - | - |
| Free cash flow | -28.51M | -30.53M | - | - | - |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ISOLF Isodiol International Inc |
- -% |
0.00 | - | - | 0.01 | 4.70 | 0.37 | -0.06 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions in Canada and the United States. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; provision of apparel and merchandising solutions; manufactures and sells hemp infused beverages; and supplies pharmaceutical products. The company is headquartered in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Marcos Agramont | CEO & Director | NA |
| Mr. Patrick Edward Ogle J.D., L.L.M. | COO & Director | NA |
| Mr. Marvin Washington | VP & Director of Bus. Devel. and Director | NA |
| Mr. Soheil Samimi | Advisor | NA |
| Mr. Andrew Stanton Alvis | Pres, Interim CFO & Director | NA |
| Mr. Kevin W. Swadish | Chief Revenue Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.